Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

PI3K Gene Mutation: early-phase trial registry

1 of 1 indexed PI3K Gene Mutation trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

PI3K Gene Mutation: 1 US clinical trial tracked, 1 recruiting.

PI3K Gene Mutation is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is OnKure, running 1 of these trials.

Enrollment posture brief

Registry condition pi3k-gene-mutation

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

PI3K Gene Mutation (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near PI3K Gene Mutation

PI3K Gene Mutation lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for PI3K Gene Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. PI3K Gene Mutation is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

OnKure 1 trials

Named interventions

Most-linked intervention names on PI3K Gene Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

OKI-219 Drug
1 trials
Atirmociclib Drug
1 trials
Tucatinib Drug
1 trials
Fulvestrant Drug
1 trials
Trastuzumab Drug
1 trials

US sites by state

Facility locations filed on PI3K Gene Mutation trials. A trial with sites in several states counts in each.

Washington 1 trials
Virginia 1 trials
Tennessee 1 trials
New York 1 trials
Nevada 1 trials
Michigan 1 trials
Massachusetts 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this PI3K Gene Mutation page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 PI3K Gene Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • OnKure sponsors the most PI3K Gene Mutation trials on record, review their full trial history before evaluating a specific study. See OnKure's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This PI3K Gene Mutation condition card totals 1 registered trials; most-linked intervention OKI-219; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.